Literature DB >> 28045876

Cytomegalovirus in the Pediatric Transplant Recipient: Where Are We Now?

Marian G Michaels1, Atul Humar.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28045876      PMCID： PMC7228584          DOI： 10.1097/TP.0000000000001627

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  11 in total

Review 1.  Cytomegalovirus infection in liver transplant recipients: updates on clinical management.

Authors:  Jasmine Riviere Marcelin; Elena Beam; Raymund R Razonable
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.

Authors:  Camille N Kotton; Deepali Kumar; Angela M Caliendo; Anders Asberg; Sunwen Chou; Lara Danziger-Isakov; Atul Humar
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

3.  Cytomegalovirus in solid organ transplantation.

Authors:  R R Razonable; A Humar
Journal:  Am J Transplant       Date:  2013-03       Impact factor: 8.086

4.  OKT3 and viral disease in pediatric liver transplant recipients.

Authors:  James S Bowman; Michael Green; Velma P Scantlebury; Saturo Todo; Andreas Tzakis; Shunzaburo Iwatsuki; Laura Douglas; Thomas E Starzl
Journal:  Clin Transplant       Date:  1991-08       Impact factor: 2.863

5.  Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.

Authors:  Atul Humar; Ajit P Limaye; Emily A Blumberg; Ingeborg A Hauser; Flavio Vincenti; Alan G Jardine; Daniel Abramowicz; Jane A L Ives; Mahdi Farhan; Patrick Peeters
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

6.  Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

Authors:  E Gane; F Saliba; G J Valdecasas; J O'Grady; M D Pescovitz; S Lyman; C A Robinson
Journal:  Lancet       Date:  1997-12-13       Impact factor: 79.321

7.  Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children.

Authors:  M Green; M Kaufmann; J Wilson; J Reyes
Journal:  Clin Infect Dis       Date:  1997-12       Impact factor: 9.079

8.  Effectiveness of Preemptive Therapy for Cytomegalovirus Disease in Pediatric Liver Transplantation.

Authors:  Emanuele Nicastro; Sara Giovannozzi; Paola Stroppa; Valeria Casotti; Anna Paola Callegaro; Alessandra Tebaldi; Claudio Farina; Michele Colledan; Lorenzo DʼAntiga
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

9.  Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.

Authors:  Giuseppe Gerna; Daniele Lilleri; Annapaola Callegaro; Antonio Goglio; Serena Cortese; Paola Stroppa; Giuliano Torre
Journal:  Transplantation       Date:  2008-07-15       Impact factor: 4.939

10.  Cytomegalovirus: Clinical virological correlations in renal transplant recipients.

Authors:  R L Simmons; C Lopez; H Balfour; J Kalis; L C Rattazzi; J S Najarian
Journal:  Ann Surg       Date:  1974-10       Impact factor: 12.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.